BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang S, Gao S, Zhao M, Liu Y, Bu Y, Jiang Q, Zhao Q, Ye L, Zhang X. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein. Cancer Lett. 2017;392:94-104. [PMID: 28192212 DOI: 10.1016/j.canlet.2017.02.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 An M, Wang W, Zhang J, Till BG, Zhao L, Huang H, Yang Y, Li T, Han L, Zhang X, Qin P, Wang Y, Zhang M, Cui H, Gao Q, Wang Z. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunol Immunother 2023;72:385-95. [PMID: 35907016 DOI: 10.1007/s00262-022-03254-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Xiong F, Wang Q, Wu G, Liu W, Wang B, Chen Y. Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow. Biomark Res 2022;10. [DOI: 10.1186/s40364-022-00415-y] [Reference Citation Analysis]
3 Sayre W, Thompson P. Prevention of Vertical Transmission of Hepatitis B Within a North Carolina Hospital System. Clin Ther 2021;43:1786-91. [PMID: 34593255 DOI: 10.1016/j.clinthera.2021.08.012] [Reference Citation Analysis]
4 Chang XJ, Shi YW, Wang J, Liu HB, Chen Y, Zhu XN, Chen YP, Yu ZJ, Shang QH, Tan L, Li Q, Jiang L, Xiao GM, Chen L, Lu W, Hu XY, Long QH, An LJ, Zou ZY, Wong VW, Yang YP, Fan JG. Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. Hepatobiliary Pancreat Dis Int 2021;20:416-25. [PMID: 34275749 DOI: 10.1016/j.hbpd.2021.06.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Lu H, Yi W, Sun F, Zeng Z, Zhang L, Li M, Xie Y. Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy. Biosafety and Health 2021;3:190-6. [DOI: 10.1016/j.bsheal.2021.05.001] [Reference Citation Analysis]
6 Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J Gastroenterol 2021; 27(26): 3971-3983 [PMID: 34326608 DOI: 10.3748/wjg.v27.i26.3971] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Wan T, Lei Z, Tu B, Wang T, Wang J, Huang F. NEDD4 Induces K48-Linked Degradative Ubiquitination of Hepatitis B Virus X Protein and Inhibits HBV-Associated HCC Progression. Front Oncol 2021;11:625169. [PMID: 33767993 DOI: 10.3389/fonc.2021.625169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lebossé F, Inchauspé A, Locatelli M, Miaglia C, Diederichs A, Fresquet J, Chapus F, Hamed K, Testoni B, Zoulim F. Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients. Sci Rep 2020;10:21097. [PMID: 33273565 DOI: 10.1038/s41598-020-78001-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Liu Z, Wang J, Yuan H, Liu L, Bu Y, Zhao M, Yang G, Feng J, Liu Y, Li J, He Q, Zhang X. IFN-α2b inhibits the ethanol enriched-HBV cccDNA through blocking a positive feedback loop of HBx/MSL2/cccDNA/HBV/HBx in liver. Biochem Biophys Res Commun 2020;527:76-82. [PMID: 32446394 DOI: 10.1016/j.bbrc.2020.04.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Cao L, Cheng H, Jiang Q, Li H, Wu Z. APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY). 2020;12:4573-4591. [PMID: 32167932 DOI: 10.18632/aging.102913] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
11 Li T, Li J, Yang Y, Han Y, Wu D, Xiao T, Wang Y, Liu T, Zhao Y, Li Y, Dai Z, Fu X. Synthesis, pharmacological evaluation, and mechanistic study of adefovir mixed phosphonate derivatives bearing cholic acid and l-amino acid moieties for the treatment of HBV. Bioorg Med Chem 2019;27:3707-21. [PMID: 31301948 DOI: 10.1016/j.bmc.2019.07.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Feng J, Yang G, Liu Y, Gao Y, Zhao M, Bu Y, Yuan H, Yuan Y, Yun H, Sun M, Gao H, Zhang S, Liu Z, Yin M, Song X, Miao Z, Lin Z, Zhang X. LncRNA PCNAP1 modulates hepatitis B virus replication and enhances tumor growth of liver cancer. Theranostics 2019;9:5227-45. [PMID: 31410212 DOI: 10.7150/thno.34273] [Cited by in Crossref: 66] [Cited by in F6Publishing: 79] [Article Influence: 16.5] [Reference Citation Analysis]
13 Liu Y, Feng J, Sun M, Yang G, Yuan H, Wang Y, Bu Y, Zhao M, Zhang S, Zhang X. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett. 2019;454:158-170. [PMID: 30981758 DOI: 10.1016/j.canlet.2019.04.008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 12.0] [Reference Citation Analysis]
14 Tan G, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. Front Microbiol 2018;9:1611. [PMID: 30072974 DOI: 10.3389/fmicb.2018.01611] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
15 Zhang Y, Wu SS, Chen XH, Tang ZH, Yu YS, Zang GQ. Tripartite Motif Containing 52 (TRIM52) Promotes Cell Proliferation in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Med Sci Monit 2017;23:5202-10. [PMID: 29089476 DOI: 10.12659/msm.907242] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]